Our Projects


The culturally adapted psychological intervention C-MAP utilizes problem solving components within a brief intervention that can be widely utilized in clinical practice. It has recently been shown that it is feasible to carry out large randomized control trials to evaluate psychological interventions in self-harm patients in low and middle income countries(14) and shows reduction in repetition of self-harm. Thus a strong rationale exists for the robust evaluation of C-MAP in order to clearly determine the clinical and cost effectiveness of this intervention.


Learning Through Play (LTP) Plus is a low-literacy, sustainable program intended to provide parents with information on the healthy growth and development of their young children. The LTP research-based activities enhance children’s development while simultaneously promoting attachment security through building parents’ ability to read and be sensitive to their children’s cues and through active involvement in their children’s development. Plus the Thinking Healthy Program (THP) which adopts ‘here and now’ problem-solving approach. THP uses cognitive behavior therapy (CBT) techniques of active listening, changing negative thinking, and collaboration with the family.


A Randomised Double Blind Placebo Controlled 12 week trial of Methotrexate added to Treatment As Usual in Early Schizophrenia. Objective of this project is to test the prediction that addition of methotrexate (commonly used anti-inflammatory and immunosuppressive drug) to treatment as usual (TAU) for patients with early schizophrenia will result in improvement in positive and negative symptoms of schizophrenia, social and cognitive function. We are recruiting participants from 4 different centres in Karachi (Abbasi Shaheed hospital, Institute of Behavioural Science, Civil Hospital, and Karwan e Hyat). Trained researchers recruit the participants, assess them against inclusion criteria of the study, take consent from them, and randomize them after completion of detailed baseline assessment. We follow participants for 3 months.


The At Risk Mental State (ARMS) describes individuals at high risk of developing schizophrenia or psychosis. The use of antipsychotics in this population is generally not supported because a large proportion of individuals with ARMS is not likely to develop psychosis. An alternative approach is where effective and relatively benign treatments are used within a clinically staged approach.


Bipolar disorder is a leading cause of disability worldwide. A high proportion of patients with bipolar disorder experience persistent depressive symptoms that do not respond to standard drug treatments. Recent evidence has suggested that anti-inflammatory treatment may reduce depressive symptoms. Minocycline is a tetracycline antibiotic with good CNS penetration that has been suggested to be effective as an adjunct drug in improving depressive symptoms. Celecoxib, a selective cyclooxygenase 2 (COX-2) inhibitor, has also shown promising results in the treatment of depressive symptoms. This is a multi-site, three-month, randomised, placebo controlled, double-blind factorial design trial of minocycline and/or celecoxib added to treatment as usual for the treatment of depressive symptoms in patients suffering from DSM-5 bipolar I or II disorder and To investigate whether the addition of Minocycline and/or celecoxib to treatment as usual (TAU) for 3 months in patients experiencing a depressive phase of bipolar disorder will lead to an improvement in depressive symptoms compared with TAU.